AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3484423 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 58
Study 31479032 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 3, 6.25, 12.5, or 25 mg weekly intramuscular injections
Number of subjects: 24
Study 31479032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 29096836 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly lipoprotein apheresis by cascade plasma filtration (CPF) plus atorvastatin
Number of subjects: 356
Study 29096836 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin alone
Number of subjects: 356
Study 26112696 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte/Monocyte Adsorptive Apheresis (GMA)
Number of subjects: 168
Study 26112696 — intervention group
Group type: COMPARATOR
Intervention: Sham Apheresis
Number of subjects: 168
Study 23805928 — intervention group
Group type: EXPERIMENTAL
Intervention: Resourcefulness training using expressive writing (RT-EW)
Number of subjects: 40
Study 23805928 — intervention group
Group type: EXPERIMENTAL
Intervention: Resourcefulness training using verbal disclosure (RT-VD)
Number of subjects: 40
Study 23805928 — intervention group
Group type: COMPARATOR
Intervention: Comparison of RT-EW and RT-VD
Number of subjects: 40
Study 21444866 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy and surgery (CS group; n = 113)
Number of subjects: 224
Study 21444866 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (S group; n = 111)
Number of subjects: 224
Study 18649004 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg (treatment group)
Number of subjects: 68
Study 18649004 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 68
Study 16935795 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% diclofenac in 2.5% hyaluronic acid (Solaraze) with sunscreens
Number of subjects: 32
Study 16935795 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% diclofenac in 2.5% hyaluronic acid (Solaraze) alone
Number of subjects: 32
Study 16935795 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 32
Study 15112937 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 0
Study 15112937 — intervention group
Group type: EXPERIMENTAL
Intervention: Craving
Number of subjects: 0
Study 15112937 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers
Number of subjects: 0
Study 15112937 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 0
Study 15112937 — intervention group
Group type: EXPERIMENTAL
Intervention: Promising medications
Number of subjects: 0
Study 15112937 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic medications
Number of subjects: 0
Study 11254068 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based multisystemic therapy (MST)
Number of subjects: 113
Study 11254068 — intervention group
Group type: COMPARATOR
Intervention: Hospitalization
Number of subjects: 113
Study 9325830 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and training package for leg ulcer management
Number of subjects: 264
Study 9325830 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 264
Study 8452573 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic surgery
Number of subjects: 32
Study 8452573 — intervention group
Group type: COMPARATOR
Intervention: Closed-needle joint lavage
Number of subjects: 32
Study 8452573 — intervention group
Group type: EXPERIMENTAL
Intervention: Other intraarticular pathology
Number of subjects: 32
Study 8452573 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic surgery and Closed-needle joint lavage
Number of subjects: 32
Study 3759475 — intervention group
Group type: EXPERIMENTAL
Intervention: Fee-for-service (FFS) plan with no cost sharing (free care)
Number of subjects: 0
Study 3759475 — intervention group
Group type: COMPARATOR
Intervention: Prepaid group practice (PGP)
Number of subjects: 0
Study 29419362 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program
Number of subjects: 40
Study 26194867 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan
Number of subjects: 40
Study 26194867 — intervention group
Group type: COMPARATOR
Intervention: Non-olmesartan
Number of subjects: 40
Study 25141100 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐, 3‐ or 6‐portion F&V/d for 8 weeks (FAVRIT study)
Number of subjects: 2
Study 25141100 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐ or 5‐portion F&V/d for 16 weeks (ADIT study)
Number of subjects: 2
Study 25141100 — intervention group
Group type: COMPARATOR
Intervention: Control group (no F&V intake)
Number of subjects: 2
Study 22479883 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA morphine
Number of subjects: 40
Study 22479883 — intervention group
Group type: COMPARATOR
Intervention: All other recruited patients
Number of subjects: 40
Study 19730250 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation with helium (inspired oxygen fraction 0.35)
Number of subjects: 204
Study 19730250 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive ventilation without helium
Number of subjects: 204
Study 17394661 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine exercise treadmill testing (ETT) at 6 weeks post-PCI
Number of subjects: 136
Study 16350386 — intervention group
Group type: EXPERIMENTAL
Intervention: Low coronary perfusion pressure at 50 mmHg for 90 seconds followed by high at 80 mmHg for 90 seconds (group L‐H)
Number of subjects: 12
Study 16350386 — intervention group
Group type: EXPERIMENTAL
Intervention: High coronary perfusion pressure at 80 mmHg for 90 seconds followed by low at 50 mmHg for 90 seconds (group H‐L)
Number of subjects: 12
Study 12135589 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (24 mg/day) for 4 days and atracurium (0.3-0.6 mg/kg/h) for 2.8 days (group C)
Number of subjects: 37
Study 12135589 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (24 mg/day) for 4 days (group B)
Number of subjects: 37
Study 12135589 — intervention group
Group type: EXPERIMENTAL
Intervention: No treatment (group A)
Number of subjects: 37
Study 12135589 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-hemiplegic ICU patients)
Number of subjects: 37
Study 12135589 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 37
Study 10534610 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-session self-care intervention
Number of subjects: 0
Study 7631051 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 0
Study 7631051 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and sulindac
Number of subjects: 0
Study 7631051 — intervention group
Group type: EXPERIMENTAL
Intervention: Certain antihypertensive drugs (Ca2+ channel blockers, centrally acting alpha agonists, diuretics)
Number of subjects: 0
Study 7631051 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboxane synthase inhibitors and selective inhibitors of PGH synthase-2
Number of subjects: 0
Study 2067035 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus therapy with doxorubicin (60 mg/m2) and dacarbazine (750 mg/m2) intravenously on day 1
Number of subjects: 240
Study 2067035 — intervention group
Group type: COMPARATOR
Intervention: Infusional therapy with doxorubicin (60 mg/m2) and dacarbazine (750 mg/m2) delivered by continuous intravenous infusion for 96 hours on days 1-4
Number of subjects: 240
Study 6223483 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of lidocaine to the tube
Number of subjects: 189
Study 6223483 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lidocaine application)
Number of subjects: 189
Study 6223483 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up investigation
Number of subjects: 189
Study 6223483 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous oral contraception use
Number of subjects: 189
Study 6223483 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire investigation
Number of subjects: 189
Study 6223483 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sterilization
Number of subjects: 189
Study 30610657 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib plus dexamethasone (Cd)
Number of subjects: 0
Study 30610657 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib plus dexamethasone (Vd)
Number of subjects: 0
Study 30610657 — intervention group
Group type: COMPARATOR
Intervention: Difference between Cd and Vd
Number of subjects: 0
Study 30123243 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain cognitive training (MCT)
Number of subjects: 50
Study 30123243 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 50
Study 23768410 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent urinary catheterisation
Number of subjects: 170
Study 21079521 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab in combination with paclitaxel and carboplatin (PCB)
Number of subjects: 850
Study 21079521 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin and paclitaxel (PC)
Number of subjects: 850
Study 20467615 — intervention group
Group type: EXPERIMENTAL
Intervention: 7‐mm‐long NanoTite External Hex implants (Biomet 3i)
Number of subjects: 60
Study 20467615 — intervention group
Group type: COMPARATOR
Intervention: 10‐mm or longer implants placed in vertically augmented bone
Number of subjects: 60
Study 20467615 — intervention group
Group type: COMPARATOR
Intervention: Vertical bone augmentation
Number of subjects: 60
Study 20467615 — intervention group
Group type: EXPERIMENTAL
Intervention: 7‐mm short implants
Number of subjects: 60
Study 17588704 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m2 over 30 min on Days 1 and 8 of a 21-day cycle (standard arm, N=33)
Number of subjects: 64
Study 17588704 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine 1000 mg/m2 at a fixed dose rate of 10 mg/m2/min on Days 1 and 8 of a 21-day cycle (FDR arm, N=31)
Number of subjects: 64
Study 15564706 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blocker (ARB) for 1 month
Number of subjects: 65
Study 15564706 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blocker (ARB) for at least 6 months
Number of subjects: 65
Study 15564706 — intervention group
Group type: COMPARATOR
Intervention: Control group (anti-hypertensive drugs other than ARB)
Number of subjects: 65
Study 11460004 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium infusion
Number of subjects: 14
Study 11460004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 9388086 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated Diagnostic Protocol (ADP)
Number of subjects: 165
Study 9388086 — intervention group
Group type: COMPARATOR
Intervention: Control (Inpatient treatment)
Number of subjects: 165
Study 7999471 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic retinoid (4-hydroxyphenylretinamide)
Number of subjects: 0
Study 7999471 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 7999471 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 0
Study 7999471 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic mastectomy
Number of subjects: 0
Study 7999471 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudopregnancy
Number of subjects: 0
Study 7999471 — intervention group
Group type: EXPERIMENTAL
Intervention: Ideal combination oral contraceptive
Number of subjects: 0
Study 7999471 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRH agonist oophorectomy
Number of subjects: 0
Study 7999471 — intervention group
Group type: EXPERIMENTAL
Intervention: Modification of estrogen metabolism
Number of subjects: 0
Study 7999471 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression of ornithine decarboxylase induction
Number of subjects: 0
Study 7999471 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of growth factors
Number of subjects: 0
Study 3297938 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg pirenzepine tablets
Number of subjects: 43
Study 3297938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 30088009 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive parenting intervention
Number of subjects: 279
Study 30088009 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (home safety)
Number of subjects: 279
Study 27881559 — intervention group
Group type: EXPERIMENTAL
Intervention: CSL112 (2 g apoA‐I per dose)
Number of subjects: 1258
Study 27881559 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose CSL112 (6 g apoA‐I per dose)
Number of subjects: 1258
Study 27881559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1258
Study 27881559 — intervention group
Group type: EXPERIMENTAL
Intervention: CSL112 (2 g apoA‐I per dose) and High-dose CSL112 (6 g apoA‐I per dose)
Number of subjects: 1258
Study 23445124 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 years of early intervention (EI) service
Number of subjects: 360
Study 23445124 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 years of early intervention (EI) service
Number of subjects: 360
Study 23445124 — intervention group
Group type: COMPARATOR
Intervention: 4 years of standard care
Number of subjects: 360
Study 22554598 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg prasugrel
Number of subjects: 64
Study 22554598 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg prasugrel
Number of subjects: 64
Study 22554598 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg prasugrel
Number of subjects: 64
Study 20808309 — intervention group
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20 at doses of 160 or 320 IU m(‐2)
Number of subjects: 71
Study 20808309 — intervention group
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20 with undetectable circulating arginine for >=4 weeks
Number of subjects: 71
Study 20808309 — intervention group
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20 with undetectable circulating arginine for <4 weeks
Number of subjects: 71
Study 18296324 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium fortified milk (Ca milk)
Number of subjects: 345
Study 18296324 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D fortified milk (CaD milk)
Number of subjects: 345
Study 18296324 — intervention group
Group type: COMPARATOR
Intervention: Control group (unsupplemented)
Number of subjects: 345
Study 16049208 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea angustifolia extracts (three preparations: supercritical carbon dioxide, 60% ethanol, 20% ethanol)
Number of subjects: 399
Study 16049208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study 16049208 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea angustifolia extracts
Number of subjects: 399
Study 12823436 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% vitamin C cream
Number of subjects: 0
Study 12823436 — intervention group
Group type: COMPARATOR
Intervention: Excipient (control)
Number of subjects: 0
Study 10383011 — intervention group
Group type: COMPARATOR
Intervention: Calcium acetate (CaAC)
Number of subjects: 28
Study 10383011 — intervention group
Group type: COMPARATOR
Intervention: Calcium ketoglutarate (CaKE)
Number of subjects: 28
Study 8538344 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography
Number of subjects: 119
Study 8538344 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic retrograde cholangiography (ERC)
Number of subjects: 119
Study 8538344 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy with instrumental exploration
Number of subjects: 119
Study 8538344 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall morbidity rate
Number of subjects: 119
Study 1523350 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg pm
Number of subjects: 0
Study 1523350 — intervention group
Group type: COMPARATOR
Intervention: Probucol 500 mg bi
Number of subjects: 0
Study 6592034 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiagent induction and single-agent maintenance chemotherapy with randomization to an immunotherapy arm.
Number of subjects: 87
Study 6592034 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective surgical splenectomy performed for 42 patients at the completion of 3 months of induction therapy.
Number of subjects: 87
Study 30279015 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200mg twice daily
Number of subjects: 472
Study 30279015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 472
Study 30279015 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 472
Study 29546669 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplantation of collagen/UC-MSCs
Number of subjects: 0
Study 29546669 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplantation of UC-MSCs
Number of subjects: 0
Study 27397802 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation through self‐management program (intervention group)
Number of subjects: 141
Study 27397802 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 141
Study 24284444 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 g · kg(‐1) · d(‐1) protein (2 × RDA)
Number of subjects: 39
Study 24284444 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.4 g · kg(‐1) · d(‐1) protein (3 × RDA)
Number of subjects: 39
Study 24284444 — intervention group
Group type: COMPARATOR
Intervention: 0.8 g · kg(‐1) · d(‐1) protein (RDA)
Number of subjects: 39
Study 24284444 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy deficit (ED)
Number of subjects: 39
Study 24284444 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diets
Number of subjects: 39
Study 21309652 — intervention group
Group type: EXPERIMENTAL
Intervention: Early hard palate repair (EarlyHPR) at 12 months
Number of subjects: 34
Study 21309652 — intervention group
Group type: EXPERIMENTAL
Intervention: Late hard palate unrepaired (LateHPU) at 36 months
Number of subjects: 34
Study 21309652 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched for gender and age)
Number of subjects: 34
Study 20456437 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 122
Study 20456437 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 122
Study 20456437 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost
Number of subjects: 122
Study 20456437 — intervention group
Group type: COMPARATOR
Intervention: Bimatoprost, Latanoprost, Travoprost
Number of subjects: 122
Study 17389553 — intervention group
Group type: EXPERIMENTAL
Intervention: Arundic acid 2 mg/kg/h
Number of subjects: 48
Study 17389553 — intervention group
Group type: EXPERIMENTAL
Intervention: Arundic acid 4 mg/kg/h
Number of subjects: 48
Study 17389553 — intervention group
Group type: EXPERIMENTAL
Intervention: Arundic acid 6 mg/kg/h
Number of subjects: 48
Study 17389553 — intervention group
Group type: EXPERIMENTAL
Intervention: Arundic acid 8 mg/kg/h
Number of subjects: 48
Study 17389553 — intervention group
Group type: EXPERIMENTAL
Intervention: Arundic acid 10 mg/kg/h
Number of subjects: 48
Study 17389553 — intervention group
Group type: EXPERIMENTAL
Intervention: Arundic acid 12 mg/kg/h
Number of subjects: 48
Study 17389553 — intervention group
Group type: EXPERIMENTAL
Intervention: Arundic acid (all doses)
Number of subjects: 48
Study 17389553 — intervention group
Group type: EXPERIMENTAL
Intervention: Arundic acid (elderly patients)
Number of subjects: 48
Study 16314642 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A: cyclophosphamide/doxorubicin and surgery
Number of subjects: 0
Study 16314642 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B: carboplatin, etoposide, ifosfamide, and surgery
Number of subjects: 0
Study 16314642 — intervention group
Group type: EXPERIMENTAL
Intervention: MYCN nonamplified, hyperdiploid tumors
Number of subjects: 0
Study 16314642 — intervention group
Group type: EXPERIMENTAL
Intervention: MYCN nonamplified, diploid tumors
Number of subjects: 0
Study 16314642 — intervention group
Group type: EXPERIMENTAL
Intervention: MYCN amplified, hyperdiploid tumors
Number of subjects: 0
Study 16314642 — intervention group
Group type: EXPERIMENTAL
Intervention: MYCN amplified, diploid tumors
Number of subjects: 0
Study 11923692 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapa
Number of subjects: 2
Study 11923692 — intervention group
Group type: COMPARATOR
Intervention: MMF
Number of subjects: 2
Study 9449497 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedding encasement with microfine fibers (Allerguard encasing)
Number of subjects: 57
Study 7618964 — intervention group
Group type: EXPERIMENTAL
Intervention: Pouch and Roux‐en‐Y (PR)
Number of subjects: 30
Study 7618964 — intervention group
Group type: COMPARATOR
Intervention: Simple Roux‐en‐Y (RY)
Number of subjects: 30
Study 7618964 — intervention group
Group type: COMPARATOR
Intervention: Pouch and interposition (PI)
Number of subjects: 30
Study 2404087 — intervention group
Group type: EXPERIMENTAL
Intervention: IV oxacillin
Number of subjects: 92
Study 2404087 — intervention group
Group type: COMPARATOR
Intervention: IV placebo using D5W
Number of subjects: 92
Study 2404087 — intervention group
Group type: COMPARATOR
Intervention: Change of the catheter to a new site every 72 hours
Number of subjects: 92
Study 326847 — intervention group
Group type: EXPERIMENTAL
Intervention: metaproterenol 0.5% nebulized in physiologic saline
Number of subjects: 30
Study 326847 — intervention group
Group type: COMPARATOR
Intervention: isoproterenol 0.05% nebulized in physiologic saline
Number of subjects: 30
Study 31630690 — intervention group
Group type: EXPERIMENTAL
Intervention: FiO2-C (in addition to routine manual control (RMC) of FiO2)
Number of subjects: 2340
Study 31630690 — intervention group
Group type: COMPARATOR
Intervention: RMC only (control group)
Number of subjects: 2340
Study 31630690 — intervention group
Group type: EXPERIMENTAL
Intervention: FiO2-C (in addition to RMC)
Number of subjects: 2340
Study 28539618 — intervention group
Group type: EXPERIMENTAL
Intervention: STII+ exenatide
Number of subjects: 129
Study 28539618 — intervention group
Group type: COMPARATOR
Intervention: STII only
Number of subjects: 129
Study 26222126 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-085 4 g/day
Number of subjects: 210
Study 26222126 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-085 2 g/day
Number of subjects: 210